Our published work covers the operational and contractual realities of bioprocess consulting in the biopharmaceutical sector. Each article is grounded in direct project experience.
For emerging biotechs, the transition from early development into the clinic can expose CMC gaps quickly, from manufacturing decisions made too early to CDMOs that are not the right fit. The post makes the case for an experienced CMC and CDMO strategy partner covering development planning, CDMO identification and oversight, tech transfer, risk mitigation, and clinical to commercial planning.
Read on LinkedInManufacturing readiness can quickly become one of the biggest barriers to clinical milestones, financing, and commercialization for emerging CGT companies. The post walks through the familiar warning signs, from processes that work but do not scale to CDMO strategies misaligned with development timelines, and how EBS assesses readiness, prioritizes risks, and builds practical roadmaps to close the gaps.
Read on LinkedInA look at how EBS streamlines onboarding of highly qualified, highly experienced candidates from its talent pool, with strong process validation, process characterization, technology transfer, MSAT, and continued process verification resources, and novel platforms that make contract engagement more cost effective and timely.
Read on LinkedInIn biologics, the wrong consulting decision can create costly delays, regulatory challenges, and avoidable development risk. The right partner goes beyond credentials: identifying risks before they become costly problems, strengthening CMC strategies, navigating regulatory expectations, and bridging strategy and execution as an extension of your team.
Read on LinkedInTechnology transfer is often treated as the final step before manufacturing, when in reality it is where many of the hardest problems begin. The post covers six common pitfalls, including documentation that captures the process but not the knowledge, underestimated site to site differences, scale up treated as simple multiplication, late analytical comparability, and the overlooked human element.
Read on LinkedInA promising molecule is only part of the equation; the real challenge is translating it into a robust, scalable, commercially viable drug product. Key considerations span formulation behavior, process robustness, analytical characterization linking CQAs to process parameters, scale up and technology transfer, and delivery device compatibility.
Read on LinkedInA short reflection on what project and program managers face when internal resources cannot match timeline pressure, and when bringing in qualified outside contractors becomes the right move.
Read on LinkedInA brief note on the firm's mission to support those designing the next generation of therapeutic drugs and cell therapies, with manufacturing design, characterization, scale up, optimization, and validation expertise.
Read on LinkedInA perspective piece on the institutional knowledge EBS principals bring after decades of watching the field evolve, from early recombinant DNA work through monoclonal antibodies, antibody drug conjugates, and the shift from stainless steel to single use systems.
Read on LinkedInA case for bringing qualified bioprocess consultants in early during product development. The argument focuses on how early technical depth compresses timelines, strengthens regulatory position, and avoids the rework costs that follow underqualified early decisions.
Read on LinkedInThe opening installment examines why biopharma companies engage contract resources, the historical reliance on full time staff, and the rise of CROs, CDMOs, and boutique providers across the modern landscape.
Read on LinkedInThe second installment defines CROs and CDMOs grounded in FDA guidance, walks through where each fits in the drug development arc, and introduces EBS as a boutique alternative to traditional staffing agencies.
Read on LinkedInThe final installment looks at how the contract services market is shifting, including the move from W2 staffing models toward 1099 independent contractors and what that means for skill levels, retention, and engagement quality.
Read on LinkedInIf a piece here raised a question or you have a bioprocess challenge worth a conversation, send us a note. A principal responds to every inquiry within one business day.
Start a conversation